Brighton-based iCardiac Technologies Inc. and SNBL CPC Japan will collaborate on cardiac safety studies in Japan, officials of the firms announced this week.
The collaboration will involve both Thorough QT studies, as well as QT assessment in Phase I studies. In cardiology, the QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle. The companies also plan to partner to educate the Japanese pharmaceutical market on scientific and regulatory changes enabling QT assessment as part of Phase I studies.
“We are honored to be working with SNBL group, a preeminent provider of clinical trials services. ICardiac has been at the forefront of developing, validating and popularizing the use of early QT data as an alternative to doing a TQT study, and we are extremely pleased to have a partner to offer these advanced services in the Japanese market,” said Alex Zapesochny, president and CEO of iCardiac Technologies.
ICardiac specializes in cardiac safety and respiratory studies. Customers include eight of the top 10 global pharmaceutical companies, the company said. The Brighton company employs some 165 people.
9/8/2016 (c) 2016 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email [email protected]